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LETTER TO THE EDITOR
Investigating heredity in cutaneous T-cell lymphoma in a
unique cohort of Danish twins
Blood Cancer Journal (2017) 7, e517; doi:10.1038/bcj.2016.128;
published online 20 January 2017
Cutaneous T-cell lymphomas (CTCLs) are uncommon but poten-
tially fatal malignancies. The most prevalent clinical forms of CTCL
are mycosis fungoides (MF) and the more aggressive leukemic
variant, Sézary syndrome (SS).1,2 Although the etiology is largely
unknown, some lines of evidence indicate that genetic factors and
heredity play a role in CTCL. Thus, independent studies reported
on strong linkage disequilibrium between MF/SS and speciﬁc HLA-
class II allotypes in Caucasians and Ashkenazi, indicating the
existence of a signiﬁcant genetic predisposition to CTCL.3,4
Moreover, examples of CTCL occurring conjointly in monozygotic
twin pairs have been reported5,6 further suggesting a possible
relevance of genetic factors in the CTCL etiology. However,
genetic studies in multi-generation families and larger cohorts of
twins have never been conducted. Accordingly, we have taken
advantage of the Danish Twin Register and other nationwide
population-based registers, to study heritability, predisposition to
infectious diseases, comorbidity, hospitalizations and mortality for
a 30+-year period in a cohort of 42 twins with CTCL (case twins)
and their 42 co-twins, 420 age- and sex-matched twin controls
(case controls) and their 420 co-twin controls. The 42 twin pairs
comprised 13 monozygotic and 27 dizygotic twin pairs, whereas
two twin pairs were of unknown zygosity. Patient characteristics of
the CTCL case twin cohort are shown in Supplementary Table 1.
Female–male ratio was 1:1.8 and the average age at time of the
CTCL diagnosis was 53 years (range: 5–85 years) showing that case
twins with CTCL did not differ in terms of age at onset and
female–male ratio from what has been described in other cohorts
of Caucasian patients with CTCL.7–9 Likewise, the mortality was
2.7-fold increased in the case twins compared with the case–
controls, adjusted HR 2.65 (95% conﬁdence interval (CI) 1.66–4.24)
(Table 1), further indicating that the CTCL cases represented a
typical CTCL cohort.9 Surprisingly, all twin pairs were discordant
for CTCL, that is, none of the co-twins were diagnosed with CTCL.
Importantly, all co-twins were monitored from birth until 1 June
2015 or death and none were lost to follow-up. On average, the
co-twins that were alive at the time of case diagnosis were
monitored for 20 years (range: 3–40 years) after the case twins
were initially diagnosed with CTCL. As none of the co-twins were
diagnosed with CTCL within a period of minimum 3 years and up
to a maximum of 40 years after the corresponding case twin was
diagnosed with CTCL, our ﬁndings indicated that the complete
absence of CTCL in the co-twins was not a result of a short
observation time.
Although none of the co-twins developed CTCL, we examined
whether they were diagnosed with other hematological malig-
nancies or had an increased frequency of cancer in general.
Importantly, none of the co-twins were diagnosed with non-
Hodgkin- or Hodgkin lymphomas (Table 2, upper part). Moreover,
the frequency of breast cancer, cancers in the respiratory organs
and other malignancies was similar among co-twins and co-twin
controls (Table 2, upper part, second column versus forth column
and data not shown) indicating that the risk of lymphoma and
other cancers in co-twins was similar to that of the control
population. The frequency of cancer other than lymphoma was
comparable in case twins and co-twins (Table 2, upper part, ﬁrst
versus second column). As CTCL patients have an increased risk of
infectious diseases such as pneumonia and sepsis (reviewed in
Willerslev-Olsen et al.10), we compared the frequency of infectious
diseases in case- and co-twins and the corresponding control
cohorts. As expected,11,12 the frequency of pneumonia and sepsis
was signiﬁcantly higher for the CTCL cases (36% and 17%,
respectively) than for the case–controls (17% and 4%, respectively,
Table 2, upper part), supporting the notion that CTCL patients
carry an increased risk of infections due to an impaired immune
defense (reviewed in Girardi et al.1 and Willerslev-Olsen et al.10).
Restricting the analysis to monozygotic twins showed the same
picture, that is, a higher frequency of pneumonia and sepsis
among CTCL cases than case–controls (Table 2, lower part). In
contrast, the frequency of pneumonia and sepsis in co-twins was
14% and 2%, respectively, which was similar to the frequency seen
in co-twin controls (12% and 5%, respectively, Table 2, upper part,
column two versus column four). The frequency in co-twins of
other infectious diseases was also similar to the frequency in the
controls (data not shown) indicating that co-twins—unlike their
CTCL case twins—did not display an increased risk of retracting
infectious diseases and chronic infections. In support, the
frequency of hospitalization was not increased in the co-twins
when compared with the co-twin control population (Table 2,
upper part, column two versus column four). The frequency of
common diseases such as ischemic heart disease, hypertension
and chronic obstructive pulmonary disease was also similar in co-
twins and co-twin controls (Table 2, upper part, column two versus
column four), indicating that the overall morbidity and disease
spectrum in co-twins was very similar to that seen in the control
population and distinctly different from their CTCL case twins.
Indeed, we found no difference in mortality between co-twins and
co-twin controls, adjusted HR 1.08 (95% CI 0.65–1.82) (Table 1),
Table 1. Mortality in the CTCL cases, co-twins, case–controls and co-twin controls
Mortality n Deaths HR crude (95% CI) HR adjusteda (95% CI)
Case versus case–control (ref.) 461 144 2.65 (1.66–4.22) 2.65 (1.66–4.24)
Case versus co-twin (ref.) 70 23 1.90 (0.81–4.48) 1.91 (0.81–4.50)
Co-twin versus co-twin control 449 160 1.08 (0.64–1.81) 1.08 (0.65–1.82)
Abbreviations: ref., reference. aAdjusted for sex.
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whereas the mortality was increased in the CTCL cases compared
with their co-twins, adjusted HR 1.91 (95% CI 0.81–4.50) (Table 1).
Causes of death were predominated by malignant diseases in the
CTCL case cohort, accounting for 67% of all deaths, whereas
malignancy accounted for 31%, 20% and 29% of all deaths in the co-
twin, case–control and co-twin control cohorts, respectively (data
not shown), further supporting that the CTCL cases represented a
typical CTCL cohort whereas the co-twins were similar to the
background population in terms of morbidity and mortality.
As mentioned above, the ﬁnding that none of the co-twins were
diagnosed with CTCL was surprising given the previous case
reports of CTCL concordance in two twin pairs5,6 and no reports of
discordant twins. However, the result was very clear as none of the
co-twins were diagnosed with CTCL or other non-Hodgkin
lymphomas. Likewise, none of the co-twins were assigned other
differential cancer diagnosis that could have masked an under-
lying CTCL. Thus, we found no indications of CTCL being
misdiagnosed or overlooked in any of the co-twins. Indeed, if
CTCL had been overlooked or misdiagnosed in the co-twins, it
would have been expected that affected co-twins would have
displayed the typical pattern of comorbidity seen in case-twins,
but they did not. Importantly, all co-twins were followed for 20
years (range: 3–40 years) after the corresponding case twin was
ﬁrst diagnosed with CTCL and until termination of the study
period (1 January 2015) or death, indicating that the absence of
CTCL in co-twins was not a result of an insufﬁcient (too short)
observation time. Indeed, in some cases co-twins were followed
for 35–40 years without developing the disease. Moreover, none
of the co-twins were lost-to-follow-up due to other unrelated
causes such as immigration or loss of health insurance (as health
care are free of charge). Taken together, our ﬁndings indicate the
difference between case- and co-twins was real and reﬂected a
true difference in CTCL morbidity and comorbidity between the
groups. Thus, it may be concluded that there was no familial
aggregation of CTCL in the present cohort of Danish twin pairs.
Another interesting issue in the present study was whether or
not susceptibility to infectious diseases was an independent
feature or linked to the cancer itself. To address whether case
twins displayed a pre-disposition for bacterial infections, we
examined whether bacterial infection was diagnosed before or
after the date the cancer was ﬁrst diagnosed. Only one patient
was diagnosed with an infectious disease before the cancer was
diagnosed and one patient was simultaneously diagnosed with
cancer and bacterial infection, whereas the rest were diagnosed
after the cancer was ﬁrst diagnosed (data not shown). The present
ﬁndings that co-twins—unlike case twins—did not display an
enhanced frequency of infectious diseases when compared with
the control populations were important as they showed that there
was no evidence of familial risk in relation to susceptibility to
contract serious infectious diseases in the present cohort of
Danish twin pairs. Although our data do not exclude the possibility
that susceptibility to infections is a primary etiological factor, they
strongly support the notion that a high risk of severe infections in
CTCL patients is a secondary event to cancer development.10,13
In conclusion, we found discordance for CTCL in the present
cohort of twin pairs. On the basis of clinical characteristics,
morbidity, hospitalization and mortality the cohort of CTCL cases
represented a typical CTCL patient cohort, whereas the co-cases
represented the general population. Thus, our nationwide twin
study which included all hospitalizations for a 30+ -year period
was not able to detect any familial aggregation of CTCL and CTCL-
associated susceptibility to severe infectious diseases. As the ﬁrst
CTCL study in a cohort of twin pairs, the present ﬁndings may
therefore have important future implications for genetic counsel-
ing and our understanding of the etiology of CTCL.
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